HealthcareServices

Antibiotic Resistance Market Forecast: How Big Will It Be by 2030?

February 19, 2026February 19, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the antibiotic resistance market from 2026–2035 with trusted insights from The Business Research Company

How is the Antibiotic Resistance Market size predicted to change over the forecast window of 2026–2035?

The antibiotic resistance market size has experienced robust expansion in recent times. This market is projected to expand from $12.85 billion in 2025 to $13.73 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.8%. Historically, this growth has stemmed from factors such as extensive antibiotic misuse, a rise in hospital-acquired infections, the increased application of broad-spectrum antibiotics, the scarcity of new antibiotics, and the growing occurrence of resistant pathogens.

The antibiotic resistance market is projected to experience substantial growth in the upcoming years, with its size anticipated to reach $18.22 billion by 2030, reflecting a compound annual growth rate (CAGR) of 7.3%. This expansion during the forecast period is primarily attributed to increased investments in antimicrobial research and development, the growing adoption of precision diagnostics, the expansion of global resistance surveillance networks, a rising focus on alternative therapies, and increasing public-private partnerships. Furthermore, significant trends expected during this period include a greater emphasis on novel antibiotic development, the rising adoption of combination drug therapies, the growing use of rapid diagnostic testing, the expansion of antimicrobial stewardship programs, and enhanced surveillance of resistant pathogens.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12131&type=smp

Which Drivers Are Contributing To The Expansion Of The Antibiotic Resistance Market?

The increasing occurrence of drug-resistant infections is expected to propel the growth of the antibiotic-resistance market going forward. These infections are conditions caused by resistant bacteria, leading to illnesses that are considerably more difficult or impossible to cure. Antimicrobial resistance drugs assist in treating various drug-resistant infections by enhancing antibiotic treatment outcomes for both target and nontarget pathogens, contingent on the specific resistance mechanisms and the microbiome community interaction structure. For example, in November 2025, according to the UK Health Security Agency, a UK-based government agency responsible for all health security in England, the number of deaths among individuals with antibiotic-resistant infections rose from 2,041 in 2023 to 2,379 in 2024, reflecting an increase of 338 deaths over the course of a single year. Consequently, the prevalence of drug-resistant infections is driving the antibiotic resistance market.

What Segment Classifications Make Up The Antibiotic Resistance Market?

The antibiotic resistance market covered in this report is segmented –

1) By Drug Class: Beta Lactum Antibiotic, Cephalosporins, Quinolones Antibiotics, Macrolide Antibiotics, Tetracyclines, Oxazolidinones, Other Drug Classes

2) By Pathogen: Staphylococcus Aureus, Staphylococcus Pneumonia, Neisseria Gonorrhoeae, Enterococcus Faecium, Escherichia Coli, Klebsiella Pneumonia, Shigella, Clostridium Difficile, Other Pathogens

3) By Disease Type: Urinary Tract Infection, Intra-Abdominal Infection, Blood Stream infections, Clostridium Difficile Infections, Other Disease Types

4) By Mechanism Of Action: Protein Synthesis Inhibitors, Cell Wall Synthesis Inhibitors, RNA Synthesis Inhibitors, DNA Synthesis Inhibitors, Other Mechanism Of Actions

5) By End Users: Hospitals, Homecare, Specialty Clinics, Other End-users

Subsegments:

1) By Beta Lactam Antibiotics: Penicillins, Cephalosporins, Carbapenems, Monobactams

2) By Cephalosporins: First-generation, Second-generation, Third-generation, Fourth-generation

3) By Quinolones Antibiotics: Fluoroquinolones, Other Quinolones

4) By Macrolide Antibiotics: Erythromycin, Azithromycin, Clarithromycin

5) By Tetracyclines: Doxycycline, Minocycline, Tetracycline

6) By Oxazolidinones: Linezolid, Tedizolid

7) By Other Drug Classes: Glycopeptides, Lipopeptides, Streptogramins, Polymyxins

Which Trends Are Influencing The Performance And Direction Of The Antibiotic Resistance Market?

Leading companies in the antibiotic resistance market are concentrating on developing innovative products to improve treatment efficacy, ensure patient safety, and tackle the increasing challenge of multi-drug resistant (MDR) infections. For example, in January 2023, Alkem Laboratories Limited, an India-based pharmaceutical company, introduced Zidavi, a novel antibiotic designed to combat MDR infections, enhancing its availability, affordability, and accessibility while saving the lives of critically ill patients. Zidavi represents a unique combination of ceftazidime and avibactam, effective in treating infections caused by MDR gram-negative pathogens. Supplied as a sterile powdered concentrate for reconstitution, each single-dose vial contains ceftazidime pentahydrate equivalent to 2 g ceftazidime and avibactam sodium equivalent to 0.5 g avibactam. It offers an effective alternative for managing hospital-acquired pneumonia (HAP) and severe intra-abdominal infections (IAIs) caused by pathogens resistant to meropenem and colistin.

Which Major Firms Are Strengthening Their Position In The Antibiotic Resistance Market?

Major companies operating in the antibiotic resistance market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd, AbbVie Inc., Novartis AG, Merck and Co. Inc., Bristol-Myers Squibb, Sanofi S.A., AstraZeneca, GlaxoSmithKline Plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Astellas Pharma, Daiichi Sankyo, Chugai Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Paratek Pharmaceuticals Inc., Basilea Pharmaceutica Ltd., Theravance Biopharma Inc., Nabriva Therapeutics Plc, Seres Therapeutics Inc., Armata Pharmaceuticals Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/antibiotic-resistance-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Antibiotic Resistance Market?

North America was the largest region in the antibiotic resistance market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibiotic resistance market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Antibiotic Resistance Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12131&type=smp

Browse Through More Reports Similar to the Global Antibiotic Resistance Market 2026, By The Business Research Company

Veterinary Antibiotics Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-antibiotics-global-market-report

Multidrug Resistant Bacteria Market Report 2026

https://www.thebusinessresearchcompany.com/report/multidrug-resistant-bacteria-global-market-report

Antibiotics Market Report 2026

https://www.thebusinessresearchcompany.com/report/antibiotics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795